RecruitingPhase 2NCT07533942

A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

A Phase 2 Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP3507 (ONC206) in Adults With Recurrent Grade 2 or 3 Meningioma

Sponsor

Jazz Pharmaceuticals

Enrollment

30 participants

Start Date

Jul 16, 2026

Study Type

INTERVENTIONAL

Conditions

Meningioma

Summary

This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called JZP3507 for people with meningioma. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.